Motus GI

Motus GI is a medical technology company dedicated to improving endoscopy outcomes and experiences. The company is currently focused on bringing to market the Pure-Vu System, which is designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The Pure-Vu System has the potential to improve the colonoscopy experience for physicians, patients, and payers by diminishing the dependence on preprocedural preparations, thereby enhancing the quality and cost effectiveness of the exam. The Pure-Vu System is a 510(k) U.S. FDA-cleared medical device indicated for cleaning a poorly prepped colon during the colonoscopy procedure, thus decreasing the dependence on preprocedural prep regimens to achieve a thorough colonoscopy. The device fits over most standard colonoscopes, allowing the physician to clean poorly prepped colons in a safe and effective manner to gain clear visualization of the colon mucosa. The Pure-Vu System has received CE mark approval in Europe and FDA clearance to market Pure-Vu Slim Sleeve, a compatible extension to the Pure-Vu System for slim colonoscopies. In 2020, the company received AMAR approval in Israel and CE mark approval for its Gen2 Pure-Vu System.

Motus GI has raised $64.5M in total funding across 5 rounds. The company is currently at the Public stage. Key investors include Undisclosed Investor(s), Kreos Capital, Ascent Biomedical Ventures.

Motus GI operates in Health Tech & Life Sciences, Medical Devices, Diagnostics Devices, with core technologies in Sensing. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

Motus GI is based in Keren HaYesod 22, Tirat Carmel, Israel, North District. The company also has offices abroad.